NCT00982995终止2 期
UMCC 2008.048 Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- To Determine the Complete Response (no Vomiting and no Need for Nausea Rescue Medication) in Terminally Ill Patients Suffering From Nausea and/or Vomiting, Treated With Palonosetron.
研究概览
简要总结
The primary objective of this study is to determine the complete response (no vomiting and no need for other medications to treat nausea) in terminally ill patients suffering from nausea and/or vomiting, who are treated with palonosetron. Another objective is to determine the partial response (relief of nausea and vomiting to the extent that the patient wishes to continue treatment with palonosetron) after being treated with palonosetron. Palonosetron is currently approved by the FDA to prevent nausea and vomiting associated with chemotherapy. The investigators are testing this medication to see if it can help to relieve nausea and vomiting not associated with chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must be at least 18 years old.
- •Patient must have a terminal diagnosis, with estimated survival of 6 months or less.
- •Patients must have nausea and/or vomiting, not relieved with 1 or more anti-nausea medications. If the patient is treated with an anti-nausea medication, a minimum of 2 hours should pass to ensure that the medication is given a chance to be effective. If there is no relief after 2 hours, then the patient may be treated with palonosetron.
- •Patient's medications must be reviewed. Any medications possibly causing nausea should be stopped if possible. For example, if an opiate is suspected of causing nausea, another opiate should be substituted. However, if this is not effective, or if a medication change cannot be made, then the patient would be eligible for this study.
- •Patient must be able to understand and sign informed consent
- •Patients who have a bowel obstruction that will not be relieved by surgery may be enrolled. This includes patients whose obstruction is technically unresectable, or who are medically too ill to endure a surgery, or who refuse surgical intervention for any reason
排除标准
- •Patient has received chemotherapy in the past 28 days.
- •Assessment of possible causes of the nausea and vomiting should be done and recorded. If a reversible cause of the nausea is identified, that cause should be treated if possible. If the treatment relieves the nausea, then the patient is excluded from this study. Possible reversible causes of nausea and vomiting that should be excluded are:
- •Other medical conditions such as benign positional vertigo, etc.
研究组 & 干预措施
Palonosetron
Experimental
Palonosetron 0.25 mg I.V. bolus
干预措施: Palonosetron (Drug)
结局指标
主要结局
To Determine the Complete Response (no Vomiting and no Need for Nausea Rescue Medication) in Terminally Ill Patients Suffering From Nausea and/or Vomiting, Treated With Palonosetron.
时间窗: 96 hours after dosing
次要结局
- To Determine the Partial Response (Relief of Nausea and Vomiting to the Extent That the Patient Desires Continued Dosing With Palonosetron,) in Terminally Ill Patients Suffering From Nausea and/or Vomiting, Treated With Palonosetron(96 hours after dosing)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A phase II study of palonosetron to prevent nausea and vomiting induced by chemotherapy in haematological malignancies.haematological malignanciesJPRN-UMIN000010746Hematology, Department of Medicine Kitasato University, School of Medicine50
招募中
2 期
A phase II study of palonosetron to prevent nausea and vomiting induced by CHOP therapy in malignant lymphoma cancer patients.JPRN-UMIN000008932Hematology, Department of Medicine Kitasato University, School of Medicine55
已完成
3 期
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric PatientsPostoperative Nausea and VomitingNCT01395901Helsinn Healthcare SA670
已完成
2 期
The study of efficacy and safety of palonosetron for high-risk chemotherapy induced nausea and vomiting in malignant lymphoma.Malignant lymphomaJPRN-UMIN000008966Shimane University Hospital,cancer center54
进行中（未招募）
不适用
Phase II study with Palonosetron alone in preventing chemotherapy-induced nausea and vomiting in untreated patients with aggressive Non Hodgkin?s Lymphomas who underwent moderately emetogenic chemotherapy - Palonosetron in NHpreventing chemotherapy-induced nausea and vomiting in untreated patients with aggressive Non Hodgkin?s Lymphomas who underwent moderately emetogenic chemotherapy.MedDRA version: 9.1Level: HLTClassification code 10028817Term: Nausea and vomiting symptomsEUCTR2006-003189-33-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI